Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 2004

View Archived Issues

Development of tachykinin receptor antagonists

GPC Biotech announces achievement of new milestones

Andrx receives approvable letter for valproate NDA

Sumitomo and AstraZeneca form an agreement for respiratory disease treatment

MacroPore Biosurgery to study use of adipose-derived regenerative cells for heart attack treatment

Derma Sciences acquires wound care assets

Nadag and SiREEN to form Sirenade Pharmaceuticals

Crucell and Biogen Idec sign PER.C6 technology agreement for antibody discovery programs

Regional brain function alterations found in abstaining MA abusers

Increased lipid-lowering effects of atorvastatin plus avasimibe in familial hypercholesterolemia

FP-1096 reported safe and effective in ameliorating pain in endometriosis

Epimmune completes enrollment for phase I/II trial of HIV vaccine candidate

Nastech begins a clinical trial with intranasal PYY in overweight adults

A mussel lipid extract reported to reduce inflammation in osteoarthritis of the knee

Phase II results of a recombinant human plasma protease C1 inhibitor in hereditary angioedema

Analgesic effects of ziconotide in cancer and AIDS patients

Fluconazole found more effective than itraconazole against pityriasis versicolor

Pfizer describes prinomastat metabolites and their use as MMP inhibitors

Wilex claims new urokinase inhibitors and their use as antitumor agents

Novel EP4 agonists with utility in glaucoma and bone disorders

Nippon Chemiphar patent covers new piperidine-based antioxidants

Indian scientists identify antitumor agents with antimitotic, anti-VEGF and proapoptotic activity

Mercian and Eisai present novel VEGF production inhibitors for cancer therapy

Novel potent CFTR activator for cystic fibrosis therapy

Squalene synthase inhibitors for hypercholesterolemia therapy

Trial suggests PIB compound's utility in Alzheimer's research and diagnosis

Incara completes AEOL-10150 toxicology study

Tubercin shows activity in mouse metastatic melanoma

First compound from Biolipox/NicOx collaboration enters phase II

PI-88 enters phase II melanoma trial

Positive results for Chrysalin in preclinical dental bone formation study

MacroChem updates clinical progress

Zithromax approved for once-daily three-day ABS treatment

Positive data from first human trial of Alveair insulin pulmonary technology

OSI commences rolling NDA submission for Tarceva for NSCLC

Disappointing results for interferon gamma-1b trial in advanced liver fibrosis

CytoGenix and Baylor to test aerosol gene silencing agent on mouse lung cancer

European phase II trial to test male contraceptive

CholeraGarde found immunogenic in adult patients

Successful completion of a phase II clinical trial with PHP in distributive shock

Additional favorable phase III results reported for Entereg in postoperative ileus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...